NASD · Healthcare · Diagnostics & Research · USA
Biodesix Inc is a micro cap company (market value under $300 million) in the Diagnostics & Research industry.
Biodesix is a diagnostic solutions provider offering blood-based testing services for lung disease management through its Lung Diagnostic Testing segment, which comprises five tests addressing nodule risk assessment and cancer treatment guidance. The company also provides Development Services, delivering diagnostic testing and consulting to biopharmaceutical, life sciences, and diagnostic firms.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Biodesix Inc stock.
Fairly valued: intrinsic value $23.65 per share, market price $23.25, margin of safety 1.7% (as of 2026-10-30).
A 2.7x revenue multiple, discounted for its losses, values the shares at $23.65; the price of $23.25 is 2% below that value.
All 44 Diagnostics & Research stocks
BDSX is fairly valued (as of the 2026-10-30 close). A 2.7x revenue multiple, discounted for its losses, values the shares at $23.65; the price of $23.25 is 2% below that value.
$23.65 per share (as of the 2026-10-30 close), against a market price of $23.25. That is a margin of safety of 1.7%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.